Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
AUpxe8cH0qT63p1Y
